Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17733612 | 0.98 | EPAS1 (0.32) | EPAS1ALDH1A1HTR2C | |
| SCHEMBL10149928 | 0.98 | EPAS1 (0.32) | EPAS1ALDH1A1HTR2C | |
| SCHEMBL6512104 | 0.95 | HTR2C (0.35) | HTR2CCCR5 | |
| SCHEMBL20121932 | 0.87 | CXCR4 (0.31) | EPAS1ALDH1A1 | |
| SCHEMBL5680966 | 0.86 | EPAS1 (0.35) | EPAS1 | |
| SCHEMBL20256032 | 0.86 | EPAS1 (0.35) | EPAS1ALDH1A1HTR2C | |
| SCHEMBL13351747 | 0.86 | MBTD1 (0.36) | EPAS1 | |
| SCHEMBL4129266 | 0.86 | MBTD1 (0.36) | EPAS1 | |
| SCHEMBL16877663 | 0.85 | — | — | |
| SCHEMBL433801 | 0.84 | SLC6A1 (0.34) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529359-B2 | Use of GABAA receptor modulators for treatment of itch | UNIVERSITAT ZURICH (CH) | 2022-12-20 | — | — | US | disclosed |
| US-20220152037-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF PAIN | NEUROCYCLE THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220040318-A1 | PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR | SEIKAGAKU CORPORATION (JP) | 2022-02-10 | — | — | US | disclosed |
| US-20210100814-A1 | Use of GABAA receptor modulators for treatment of itch | UNIVERSITAT ZURICH (CH) | 2021-04-08 | — | — | US | disclosed |
| US-20210015933-A1 | BIOACTIVE CARBOXYLIC ACID TYPE COMPOUND-POLYMER CONJUGATE, AND METHOD FOR MANUFACTURING THE SAME | SEIKAGAKU CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| US-10786513-B2 | Use of GABAA receptor modulators for treatment of itch | UNIVERSITAT ZURICH (CH) | 2020-09-29 | — | — | US | disclosed |
| US-20200138964-A1 | TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR | SEIKAGAKU CORPORATION (JP) | 2020-05-07 | — | — | US | disclosed |
| WO-2020067507-A1 | PRIMARY AMINE COMPOUND- OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE, AND METHOD FOR PRODUCING SAME | 生化学工業株式会社 | 2020-04-02 | — | — | WO | disclosed |
| WO-2019189876-A1 | (CARBOXYLIC ACID-TYPE COMPOUND)-POLYMER CONJUGATE HAVING BIOLOGICAL ACTIVITY, AND METHOD FOR PRODUCING SAME | 生化学工業株式会社 | 2019-10-03 | — | — | WO | disclosed |
| WO-2011000945-A9 | AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS | NENSIUS RESEARCH A/S (DK) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011000945-A2 | AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS | NENSIUS RESEARCH A/S (DK) | 2011-01-06 | — | — | WO | disclosed |
| US-20050171094-A1 | Pyrrolopyrimidine derivatives | TEIJIN, LIMITED (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1477490-A1 | PYRROLOPYRIMIDINE DERIVATIVE | TEIJIN LIMITED (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-4415684-A | POLYMER STABILIZERS | THE B. F. GOODRICH COMPANY (US) | 1983-11-15 | — | — | US | disclosed |
| US-4207228-A | POLYOLEFINS | THE B. F. GOODRICH COMPANY (US) | 1980-06-10 | — | — | US | disclosed |
| EP-0001560-A2 | UV-light-stabilized compositions containing substituted 1,5-diazacycloalkanes and 2-keto-1,5-diazacycloalkanes, novel compounds and synthesis thereof | The B.F. GOODRICH Company (US) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015933-A1 | BIOACTIVE CARBOXYLIC ACID TYPE COMPOUND-POLYMER CONJUGATE, AND METHOD FOR MANUFACTURING THE SAME | HCAR1, HCAR2, MCCC2 | EPAS1 3393/4885ALDH1A1 285/4885HTR2C 3210/4885 |
| US-20200138964-A1 | TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR | SOAT1, SLC7A1, ODC1 | EPAS1 4580/4885ALDH1A1 1001/4885HTR2C 2550/4885 |
| US-20210100814-A1 | Use of GABAA receptor modulators for treatment of itch | GABRB2, GABRB3, GABRB1 | EPAS1 3572/4885ALDH1A1 996/4885HTR2C 386/4885 |
| US-20220040318-A1 | PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR | ALG1, NGLY1, SAT1 | EPAS1 3235/4885ALDH1A1 388/4885HTR2C 2259/4885 |
| US-20050171094-A1 | Pyrrolopyrimidine derivatives | GSK3B, GSK3A, GSKIP | EPAS1 2230/4885ALDH1A1 4231/4885HTR2C 2734/4885 |
| US-11529359-B2 | Use of GABAA receptor modulators for treatment of itch | GABRB2, GABRB3, GABRB1 | EPAS1 3572/4885ALDH1A1 996/4885HTR2C 386/4885 |
| US-10786513-B2 | Use of GABAA receptor modulators for treatment of itch | GABRB2, GABRB3, GABRB1 | EPAS1 3572/4885ALDH1A1 996/4885HTR2C 386/4885 |
| US-20220152037-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF PAIN | GABRB2, GABRB1, GABBR1 | EPAS1 2850/4885ALDH1A1 820/4885HTR2C 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.